Clinical trials: Kidney Transplantation Recipients
Kidney Disease
Effects of Dexmedetomidine on Microcirculation of Kidney Transplant Recipient
The microcirculation is altered in acute kidney injury and chronic kidney disease. The microcirculation is poor in end-stage renal disease patients receiving hemodialysis.
- Trial name
- NCT02707809
- Testing
- Dexmedetomidine
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- National Taiwan University Hospital
Renal Transplant
Effects of Zortress® + Tacrolimus vs. Standard Immunosuppression on Progression of Coronary Artery Calcifications and Bone Disease in de Novo Renal Transplant Recipients
Primary objectives: A. To evaluate the effect of Zortress® versus standard immunosuppression therapy on progression of CAC as evidenced by changes in Agatston scores from baseline and at 6, and 12 months in renal transplantation…
- Trial name
- NCT01612299
- Testing
- Zortress® /Everolimus
- Where
- United States
- Sponsor
- University of Kentucky
Hypertension; Nephropathy, Renal Transplant
Effects of Nocturnal Hypertension on Sleep Quality in Renal Transplant Recipients
Nocturnal hypertension (i.e. blood pressure values >120/70 or 10% higher than diurnal values, as measured by ambulatory blood pressure monitoring, ABPM) is particularly frequent in renal transplant recipients (RTR), despite the…
- Conditions
- Hypertension; Nephropathy, Renal Transplant, Sleep Disorder
- Trial name
- NCT03651492
- Testing
- questionnaire administration
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- Federico II University
Kidney Transplant Rejection
CLinical Utility of the omnigrAf® biomarkeR Panel In The Care of kidneY Transplant Recipients
This is a prospective, multi-site, observational study with a matched control group. The primary objective is to evaluate change in renal function over time in recipients of kidney transplants who are undergoing OmniGrafTM…
- Trial name
- CLARITY (NCT05482100)
- Testing
- Patients monitored with OmniGraf testing
- Volunteers
- 500 people
- Sponsor
- Transplant Genomics, Inc.
Kidney Transplantation
A Dose Escalation Study in de Novo Renal Transplantation
The purpose of this study is to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of escalating doses of TCD601 when compared to rATG in de novo renal transplant patients.
- Trial name
- NCT04311632
- Testing
- TCD601, Tacrolimus (TAC), Corticosteroids (CS)
- Where
- 4 sites in United States
- Volunteers
- 13 people
- Sponsor
- ITB-Med LLC
Kidney Transplant Failure and Rejection, Kidney Transplant; Complications
ECP-DL Cell Infusion for Induction in Living Donor Kidney (LDK) Transplants
This is a phase 1 trial, 36 month duration for subjects with end-stage renal disease (ESRD). The objectives of the trail are1) Determine the safety of ECP-DL cell infusion in living donor renal transplant recipients.
- Trial name
- ECP (NCT07083830)
- Testing
- ECP-DL treated mononuclear cell infusion
- Volunteers
- 24 people
- Sponsor
- Northwestern University
Kidney Transplant Dysfunction
Urinary Kidney Injury Molecule-1 (KIM-1) Excretion As Biomarker for Injury in Kidney Transplant Recipients
The purpose of this study is to determine if measuring the level of a protein called Kidney Injury Molecule-1 (KIM-1) in the urine will help healthcare providers detect any problems with the transplanted kidney before the…
- Trial name
- NCT00805571
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Northwell Health
Renal Allograft Recipients
A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications
The purpose of this study is to evaluate the benefits and risks of conversion of existing adolescent kidney allograft recipients aged 12 to less than 18 years of age to a belatacept-based immunosuppressive regimen as compared to…
- Trial name
- NCT04877288
- Testing
- Belatacept, Tacrolimus, Cyclosporine A
- Where
- 38 sites in United States, Argentina and 8 more
- Volunteers
- 102 people
- Sponsor
- Bristol-Myers Squibb
Renal Transplant
Study of Enteric-coated Mycophenolate Sodium Versus Mycophenolate Mofetil in Adult de Novo Renal Transplant Patients
Purpose of study is to compare the efficacy of enteric-coated mycophenolate sodium compared to mycophenolate mofetil in Chinese patients (study conducted in China) as measured by the incidence of biopsy proven acute rejection…
- Trial name
- NCT00149903
- Testing
- Mycophenolate sodium (enteric coated)
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Novartis Pharmaceuticals
Cytomegalovirus (CMV) Infection, Kidney Transplant Recipient
Renal Ex Vivo SYN002 Perfusion to Eliminate CMV Transmission
Donor organs often carry latent Cytomegalovirus (CMV) infection that may be transmitted to the recipient. The goal of this clinical trial is to determine the safety of SYN002 treatment during Ex-Vivo Organ Perfusion (EVOP) in…
- Trial name
- RESPECT-CMV (NCT07488481)
- Testing
- SYN002
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- University Health Network, Toronto
Chronic Kidney Disease 5D, Chronic Kidney Disease 5T
Humoral and Cellular İmmune Response to SARS-CoV-2 mRNA BNT162b2 Vaccine in Children With Chronic Kidney Diseases
Coronavirus 2019 (COVID-19) infection is associated with higher morbidity and mortality in adult patients on dialysis, and kidney transplant recipients (KTRs).
- Trial name
- NCT05465863
- Testing
- SARS-CoV-2 mRNA BNT162b2 vaccine (Pfizer-BioNTech®)
- Where
- 6 sites in Turkey (Türkiye)
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Istanbul University - Cerrahpasa
Kidney Transplant Infection, Kidney Transplant Rejection
Immune Monitoring of Prevalent Kidney Transplant Recipients Using Torque Teno Virus: A Single-Center, Prospective Cohort Study
Kidney transplant recipients (KTRs) suffer from immunosuppression-related adverse events (iRAEs), such as infections and malignancy from chronic immunosuppression exposure but are also at risk of graft loss from rejection with…
- Conditions
- Kidney Transplant Infection, Kidney Transplant Rejection, Kidney Transplant; Complications
- Trial name
- TTV-KTR-SGH (NCT05836636)
- Testing
- Torque teno virus DNA measurement
- Where
- Singapore
- Volunteers
- 172 people
- Sponsor
- Singapore General Hospital
Liver Transplantation
Efficacy of Everolimus in Combination With Tacrolimus in Liver Transplant Recipients
This trial evaluated the efficacy and safety of Everolimus in combination with tacrolimus versus a standard immunosuppressive regimen concerning kidney function in liver transplant recipients.
- Trial name
- HEPHAISTOS (NCT01551212)
- Testing
- Everolimus, Tacrolimus, Corticosteroids
- Where
- 15 sites in Germany
- Volunteers
- 339 people
- Sponsor
- Novartis Pharmaceuticals
Medication Adherence
Medication Adherence in Kidney Transplant Patients: SystemCHANGE™ Results of the Turkish MAGIC Randomized Clinical Trial
The SystemCHANGETM intervention harnesses patients' established daily routines/habits, environment, and important others, as possible solutions that are reoccurring and thus reliable systems that could support medication taking…
- Trial name
- NCT06106854
- Testing
- Behavioral: SystemCHANGE, Education
- Where
- Turkey (Türkiye)
- Volunteers
- 42 people
- Sponsor
- Dokuz Eylul University
Transplantation
A Conversion Study to Assess Safety and Efficacy of a MR4 Based Immunosuppressive Regimen in Stable Kidney Recipients
Assessment of the safety and the efficacy of a tacrolimus modified release (MR4) based immunosuppressive regimen in stable kidney transplant subjects converted on a 1:1 (mg:mg) basis from a Prograf® based immunosuppressive…
- Trial name
- NCT00384137
- Testing
- Tacrolimus
- Where
- 13 sites in France, Germany and 4 more
- Volunteers
- 128 people
- Sponsor
- Astellas Pharma Inc
Kidney Transplantation
Study Comparing Graft Function in Renal Allograft Recepients Receiving Reduced or Standard Dose CsA With Sirolimus
This study evaluated renal graft function (based on calcuated creatinine clearance) 12 months after transplantation in patients receiving either a regimen of reduced dose or standard dose cyclosporine in combination with…
- Trial name
- NCT00518375
- Testing
- Rapamune® (Sirolimus), Neoral® (Cyclosporine), Corticosteroids
- Volunteers
- 250 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Urinary Tract Infections, Kidney Transplant; Complications
Double Voiding and Post-transplant UTI
Urinary tract infections (UTI) are common in kidney transplant recipients and are an important cause of illness and hospital admissions.
- Trial name
- NCT05711446
- Testing
- Double Voiding, Regular Voiding
- Where
- United States
- Volunteers
- 438 people
- Sponsor
- Weill Medical College of Cornell University
Hypertension Secondary to Kidney Transplant
Reduction of Night-time Blood Pressure in Pediatric Renal Transplant Recipients
The proposed study investigated the effect of chronotherapeutic alteration of anti-hypertensive medication on nocturnal hypertension and end-organ injury in pediatric renal transplant recipients who are non-dippers.
- Trial name
- NCT01007994
- Testing
- New Medication: Enalapril, Isradipine, Propranolol
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- Northwell Health
Kidney Transplant, Urinary Complications
Impact of Double J Catheter in Major Urological Complications in Renal Transplant Recipients
Renal transplantation is the renal replacement therapy of choice in patients with end-stage chronic kidney disease. Major urological complications such as urinary leakage, ureteral stricture and urinary tract infections are…
- Conditions
- Kidney Transplant, Urinary Complications, Double J Stent
- Trial name
- NCT07008131
- Testing
- Double J stent, No Double J stent
- Where
- Mexico
- Volunteers
- 84 people
- Sponsor
- Instituto Mexicano del Seguro Social
Kidney Transplant Recipients
The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients
The study aims to determine the short-term efficacy, mechanisms and safety of 12 weeks of dapagliflozin and semaglutide combination therapy in 20 KTR, with and without T2D.
- Trial name
- HALLMARK (NCT05938712)
- Testing
- Dapagliflozin 10 MG, Semaglutide, 1.0 mg/mL
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University Health Network, Toronto